pmid	doi	year	title	Hugo_Symbol
33509441	10.1053/j.seminhematol.2020.11.008	2022	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.	CDKN2A
33870156	10.1016/j.jhepr.2021.100250	2022	Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the <i>Mdr2</i> <sup><i>-/-</i></sup>  mouse.	CDKN2A
33932086	10.1002/1878-0261.12964	2022	An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.	CDKN2A
34115902	10.1111/ced.14798	2022	The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.	CDKN2A
34217275	10.1186/s12920-021-01023-9	2022	Hypodiploidy in a pediatric patient of T-cell acute lymphoblastic leukemia: a case report.	CDKN2A
34308104	10.1093/jncics/pkab007	2022	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.	CDKN2A
34369425	10.1097/FPC.0000000000000451	2022	The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia.	CDKN2A
34371436	10.1016/j.leukres.2021.106683	2022	Proposal and clinical application of molecular genetic risk scoring system, MRplus, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	CDKN2A
34440292	10.3390/genes12081118	2022	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	CDKN2A
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	CDKN2A
34591292	10.1007/s12185-021-03229-0	2022	Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.	CDKN2A
34657128	10.1038/s41375-021-01448-2	2022	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	CDKN2A
34670378	10.21037/apm-21-2256	2022	Neurolymphomatosis of multifocal peripheral nerve involvement: a case report.	CDKN2A
34727170	10.1182/bloodadvances.2021005522	2022	Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.	CDKN2A
34787376	10.1002/cnr2.1587	2022	Philadelphia-like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia.	CDKN2A
34807923	10.1371/journal.pone.0259674	2022	Establishment of the TBX-code reveals aberrantly activated T-box gene TBX3 in Hodgkin lymphoma.	CDKN2A
34808593	10.1016/j.cancergen.2021.10.003	2022	Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.	CDKN2A
34821038	10.1111/ijlh.13769	2022	T cell lymphoblastic lymphoma with uncommon CD20 expression.	CDKN2A
34940123	10.3390/cimb43030149	2022	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	CDKN2A
34957727	10.2478/raon-2021-0050	2022	Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience.	CDKN2A
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	CDKN2A
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	CDKN2A
35074700	10.1016/j.prp.2022.153772	2022	Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!	CDKN2A
35115489	10.1038/s41467-022-28218-7	2022	An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia.	CDKN2A
35117001	10.21037/tcr.2019.10.04	2022	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.	CDKN2A
35117454	10.21037/tcr.2019.12.79	2022	MicorRNA-148b inhibits cell proliferation and facilitates cell apoptosis by regulating DNA Methyltransferase 1 in endometrial cancer.	CDKN2A
35142151	10.3324/haematol.2021.279908	2022	A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.	CDKN2A
35247197	10.1007/s12094-022-02781-3	2022	Distinct power of bone marrow microRNA signatures and tumor suppressor genes for early detection of acute leukemia.	CDKN2A
35373885	10.1002/pbc.29575	2022	Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.	CDKN2A
35538064	10.1038/s41467-022-30050-y	2022	The genomic and transcriptional landscape of primary central nervous system lymphoma.	CDKN2A
35726642	10.1161/HYPERTENSIONAHA.122.19137	2022	Cathepsin K Deficiency Prevented Kidney Damage and Dysfunction in Response to 5/6 Nephrectomy Injury in Mice With or Without Chronic Stress.	CDKN2A
35910501	10.6004/jadpro.2022.13.5.7	2022	An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.	CDKN2A
35932035	10.1186/s12920-022-01325-6	2022	Association of IKZF1 and CDKN2A gene polymorphisms with childhood acute lymphoblastic leukemia: a high-resolution melting analysis.	CDKN2A
36000950	10.1002/pbc.29926	2022	Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.	CDKN2A
36006308	10.3390/vetsci9080393	2022	Simultaneous Analysis of the p16 Gene and Protein in Canine Lymphoma Cells and Their Correlation with pRb Phosphorylation.	CDKN2A
25289094	10.3892/ol.2014.2481	2021	Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells.	CDKN2A
28123872	10.1080/2162402X.2016.1237327	2021	IL-15 enhances the antitumor effect of human antigen-specific CD8<sup>+</sup> T cells by cellular senescence delay.	CDKN2A
31383960	10.1038/s41379-019-0323-8	2021	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.	CDKN2A
31631728	10.1080/10428194.2019.1675877	2021	The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.	CDKN2A
31701788	10.1080/17474086.2020.1690987	2021	Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools.	CDKN2A
31734690	10.1093/carcin/bgz185	2021	Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells.	CDKN2A
32255708	10.1080/10428194.2020.1747068	2021	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.	CDKN2A
32277542	10.1002/gcc.22849	2021	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.	CDKN2A
32592278	10.1002/gcc.22882	2021	Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.	CDKN2A
32598477	10.1182/bloodadvances.2019001350	2021	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	CDKN2A
32701692	10.1097/DAD.0000000000001632	2021	A Clinicopathological Study of 29 Spitzoid Melanocytic Lesions With ALK Fusions, Including Novel Fusion Variants, Accompanied by Fluorescence In Situ Hybridization Analysis for Chromosomal Copy Number Changes, and Both TERT Promoter and Next-Generation Sequencing Mutation Analysis.	CDKN2A
32751805	10.3390/cancers12082120	2021	Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.	CDKN2A
32779615	10.3960/jslrt.20019	2021	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	CDKN2A
32861279	10.1016/j.hoc.2020.05.003	2021	Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.	CDKN2A
32918521	10.1002/pbc.28704	2021	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	CDKN2A
32981916	10.3960/jslrt.20021	2021	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.	CDKN2A
33054126	10.3324/haematol.2020.262659	2021	&lt;i&gt;CDKN2A&lt;/i&gt; deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).	CDKN2A
33226554	10.1007/s12094-020-02504-6	2021	Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma.	CDKN2A
33306218	10.1002/ajh.26069	2021	CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.	CDKN2A
33316538	10.1016/j.neo.2020.11.010	2021	U-RT1 - A new model for Richter transformation.	CDKN2A
33357483	10.1016/S2352-3026(20)30353-7	2021	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.	CDKN2A
33369444	10.31557/APJCP.2020.21.12.3493	2021	Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.	CDKN2A
33435487	10.3390/genes12010079	2021	The Yin and Yang-Like Clinical Implications of the <i>CDKN2A/ARF/CDKN2B</i> Gene Cluster in Acute Lymphoblastic Leukemia.	CDKN2A
33528622	10.1007/s00428-021-03022-8	2021	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.	CDKN2A
33538126	10.1111/ijlh.13477	2021	Epigenetic analysis reveals significant differential expression of miR-378C and miR-128-2-5p in a cohort of relapsed pediatric B-acute lymphoblastic leukemia cases.	CDKN2A
33538150	10.3324/haematol.2020.260935	2021	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.	CDKN2A
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	CDKN2A
33541741	10.1016/j.arcmed.2020.12.013	2021	Copy Number Alterations are Associated with the Risk of Very Early Relapse in Pediatric B-lineage Acute Lymphoblastic Leukemia: A Nested Case-control MIGICCL Study.	CDKN2A
33720992	10.1371/journal.ppat.1009419	2021	Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes.	CDKN2A
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	CDKN2A
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	CDKN2A
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	CDKN2A
33793571	10.1371/journal.pgen.1009395	2021	Identification of common predisposing loci to hematopoietic cancers in four dog breeds.	CDKN2A
33851706	10.1042/CS20201498	2021	In utero and early-life exposure to thirdhand smoke causes profound changes to the immune system.	CDKN2A
34098582	10.1182/blood.2020007591	2021	MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.	CDKN2A
34218589	10.3760/cma.j.issn.0253-2727.2021.05.015	2021	[The characteristics and prognostic impact of NOTCH1/FBXW7 mutation and CDKN2A/B deletion in adult T-cell acute lymphoblastic leukemia patients].	CDKN2A
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	CDKN2A
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	CDKN2A
34340673	10.1186/s12885-021-08635-5	2021	Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.	CDKN2A
34406703	10.1002/ajh.26324	2021	The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.	CDKN2A
34576156	10.3390/ijms22189992	2021	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.	CDKN2A
34646650	10.7759/cureus.17598	2021	An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.	CDKN2A
26137003	10.3892/ol.2015.2986	2020	Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line.	CDKN2A
28487787	10.1155/2017/5083463	2020	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	CDKN2A
29670052	10.3390/diagnostics8020026	2020	Aneuploid CTC and CEC.	CDKN2A
29966470	10.1080/10428194.2018.1482542	2020	Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.	CDKN2A
30171027	10.3324/haematol.2017.186320	2020	Clinical and molecular characteristics of <i>MEF2D</i> fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in <i>MEF2D-HNRNPH1</i> gene fusion.	CDKN2A
30190342	10.3324/haematol.2018.196055	2020	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	CDKN2A
30250579	10.3892/ol.2018.9268	2020	Bone morphogenetic protein and activin membrane-bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF-β-induced EMT signaling pathway.	CDKN2A
30402386	10.1016/j.rmcr.2018.10.020	2020	An unusual case of chylothorax.	CDKN2A
30470842	10.1038/s41417-018-0057-7	2020	Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.	CDKN2A
30586141	10.1001/jamadermatol.2018.3662	2020	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.	CDKN2A
30592434	10.1080/07853890.2018.1564359	2020	Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.	CDKN2A
30723112	10.1182/bloodadvances.2018027672	2020	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	CDKN2A
30874617	10.1038/s41598-019-41078-4	2020	Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.	CDKN2A
30902917	10.1634/theoncologist.2018-0572	2020	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.	CDKN2A
30915242	10.1155/2019/3540487	2020	Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review.	CDKN2A
30938769	10.1093/labmed/lmz008	2020	BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.	CDKN2A
30938820	10.1093/jnci/djz043	2020	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.	CDKN2A
30963600	10.1002/ajh.25487	2020	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.	CDKN2A
31092896	10.1038/s41375-019-0473-1	2020	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.	CDKN2A
31093876	10.1007/s11033-019-04856-x	2020	The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.	CDKN2A
31123088	10.1158/0008-5472.CAN-18-2480	2020	Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.	CDKN2A
31202078	10.1016/j.leukres.2019.05.013	2020	Microarray testing as an efficient tool to redefine hyperdiploid paediatric B-cell precursor acute lymphoblastic leukaemia patients.	CDKN2A
31228652	10.1016/j.leukres.2019.05.009	2020	Prognostic gene alterations and clonal changes in childhood B-ALL.	CDKN2A
31261022	10.1016/j.leukres.2019.106177	2020	High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients.	CDKN2A
31340073	10.1002/gcc.22788	2020	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.	CDKN2A
31350265	10.1182/blood.2018890764	2020	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.	CDKN2A
31378747	10.1248/bpb.b19-00391	2020	Artemether Attenuates the Progression of Non-small Cell Lung Cancer by Inducing Apoptosis, Cell Cycle Arrest and Promoting Cellular Senescence.	CDKN2A
31410080	10.3906/biy-1810-2	2020	Systematic analysis of the frequently amplified 2p15-p16.1 locus reveals PAPOLG as a potential proto-oncogene in follicular and transformed follicular lymphoma.	CDKN2A
31611375	10.1073/pnas.1910255116	2020	Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy.	CDKN2A
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	CDKN2A
31808882	10.1182/hematology.2019000011	2020	Molecular profiling and management of mantle cell lymphoma.	CDKN2A
31869410	10.1182/bloodadvances.2019000925	2020	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.	CDKN2A
31999420	10.18388/abp.2020_2901	2020	The effects of clofarabine in ALL inhibition through DNA methylation regulation.	CDKN2A
32132242	10.1128/JVI.02168-19	2020	An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.	CDKN2A
32179411	10.1016/j.bcmd.2020.102419	2020	PEST domain NOTCH mutations confer a poor relapse free survival in pediatric T-ALL: Data from a tertiary care centre in India.	CDKN2A
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	CDKN2A
32300395	10.14740/jh329w	2020	<i>De Novo</i> Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (<i>MYC/BCL-2</i>) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.	CDKN2A
32300400	10.14740/jh327w	2020	Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion.	CDKN2A
32332702	10.1038/s41408-020-0308-3	2020	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.	CDKN2A
32345961	10.1038/s41408-020-0310-9	2020	DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma.	CDKN2A
32472610	10.1002/hon.2750	2020	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.	CDKN2A
32515032	10.1002/hon.2762	2020	High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.	CDKN2A
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	CDKN2A
32650545	10.3390/metabo10070280	2020	Potential Metabolite Nymphayol Isolated from Water Lily (<i>Nymphaea stellata</i>) Flower Inhibits MCF-7 Human Breast Cancer Cell Growth via Upregulation of Cdkn2a, pRb2, p53 and Downregulation of PCNA mRNA Expressions.	CDKN2A
32661308	10.1038/s41598-020-68311-9	2020	MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia.	CDKN2A
33085860	10.1056/NEJMoa2016272	2020	Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.	CDKN2A
33344238	10.3389/fonc.2020.584095	2020	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas.	CDKN2A
28804123	10.1038/leu.2017.251	2019	Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.	CDKN2A
29084771	10.1182/blood-2017-01-761874	2019	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.	CDKN2A
29199525	10.1080/10428194.2017.1408087	2019	Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.	CDKN2A
29348129	10.1182/blood-2017-07-796862	2019	Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantation.	CDKN2A
29382514	10.1016/j.bmhimx.2017.02.005	2019	[Epigenetic alterations in acute lymphoblastic leukemia].	CDKN2A
29407587	10.1016/j.leukres.2018.01.012	2019	High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.	CDKN2A
29446543	10.1002/pbc.27001	2019	Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.	CDKN2A
29449437	10.3324/haematol.2017.172304	2019	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.	CDKN2A
29498923	10.1200/JCO.2017.74.3617	2019	IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.	CDKN2A
29556024	10.1038/s41375-018-0046-8	2019	The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.	CDKN2A
29654170	10.1042/BSR20180331	2019	Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia.	CDKN2A
29692342	10.1182/blood-2018-01-791376	2019	Biology and treatment of Richter syndrome.	CDKN2A
29713087	10.1038/s41591-018-0016-8	2019	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.	CDKN2A
29735551	10.1158/0008-5472.CAN-17-4004	2019	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	CDKN2A
29740158	10.1038/s41375-018-0127-8	2019	Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.	CDKN2A
29755111	10.1038/s41417-018-0022-5	2019	Genomic landscape and prognostic analysis of mantle cell lymphoma.	CDKN2A
29769262	10.1182/blood-2018-03-838136	2019	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.	CDKN2A
30005850	10.1016/j.cancergen.2018.04.119	2019	Challenges in next generation sequencing analysis of somatic mutations in transplant patients.	CDKN2A
30041662	10.1186/s13045-018-0639-8	2019	Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.	CDKN2A
30069049	10.1038/s41586-018-0387-5	2019	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.	CDKN2A
30078808	10.11406/rinketsu.59.953	2019	[Genetic basis of pediatric T-cell acute lymphoblastic leukemia and its clinical impact].	CDKN2A
30125329	10.1371/journal.ppat.1007221	2019	An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.	CDKN2A
30132080	10.1007/s11912-018-0728-4	2019	Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.	CDKN2A
30144205	10.1002/gcc.22679	2019	Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides.	CDKN2A
30171453	10.1007/s11060-018-2990-6	2019	Characterization of genomic alterations in primary central nervous system lymphomas.	CDKN2A
30209976	10.1080/15384101.2018.1522912	2019	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	CDKN2A
30280491	10.1002/pbc.27496	2019	Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan.	CDKN2A
30305518	10.11406/rinketsu.59.2127	2019	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	CDKN2A
30307677	10.1002/gcc.22673	2019	Array-based CGH of primary cutaneous CD8+ aggressive EPIDERMO-tropic cytotoxic T-cell lymphoma.	CDKN2A
30360879	10.1053/j.seminoncol.2018.07.005	2019	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	CDKN2A
30446494	10.1182/blood-2018-07-865428	2019	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.	CDKN2A
30466748	10.1016/j.beha.2018.10.001	2019	Can one target T-cell ALL?	CDKN2A
30538135	10.1182/blood-2018-07-862151	2019	<i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphoma.	CDKN2A
30561492	10.1093/ajcp/aqy160	2019	Application of Fluorescence In Situ Hybridization on Cerebrospinal Fluid Cytospins for the Detection of Residual Leukemic Cells in Patients With Childhood Acute Lymphoblastic Leukemia.	CDKN2A
30578714	10.1002/gcc.22726	2019	Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.	CDKN2A
30635552	10.1038/s12276-018-0195-x	2019	CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.	CDKN2A
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	CDKN2A
30701920	10.26442/terarkh201890730-37	2019	Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia.	CDKN2A
30782609	10.1182/blood-2018-09-872549	2019	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.	CDKN2A
30830578	10.1007/s12185-019-02617-x	2019	A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.	CDKN2A
30836703	10.3390/biom9030087	2019	Dual Role of the Alternative Reading Frame ARF Protein in Cancer.	CDKN2A
30842609	10.1038/s41375-019-0430-z	2019	PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.	CDKN2A
31112375	10.1111/ijlh.13052	2019	Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.	CDKN2A
27102345	10.1038/modpathol.2016.79	2018	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	CDKN2A
27203215	10.18632/oncotarget.9413	2018	Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models.	CDKN2A
27276707	10.18632/oncotarget.9793	2018	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.	CDKN2A
27339065	10.1080/10428194.2016.1193855	2018	Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.	CDKN2A
27756164	10.1080/10428194.2016.1228925	2018	Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.	CDKN2A
27960642	10.1080/08880018.2016.1251518	2018	The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.	CDKN2A
28002793	10.18632/oncotarget.14008	2018	Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.	CDKN2A
28262675	10.1038/ncomms14581	2018	Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.	CDKN2A
28265066	10.1073/pnas.1620262114	2018	Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf<sup>-/-</sup> mouse model.	CDKN2A
28351340	10.1089/thy.2016.0254	2018	Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.	CDKN2A
28482719	10.1080/10428194.2017.1312383	2018	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.	CDKN2A
28631637	10.4103/IJPM.IJPM_466_16	2018	An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia.	CDKN2A
28652370	10.1073/pnas.1707292114	2018	Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of <i>Arf</i> tumor suppressor-deficient mice.	CDKN2A
28730642	10.1111/his.13316	2018	MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.	CDKN2A
28751478	10.1158/1055-9965.EPI-17-0360	2018	Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.	CDKN2A
28768142	10.1089/gtmb.2017.0084	2018	Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 Gene Polymorphisms to Acute Lymphoblastic Leukemia in a Yemeni Population.	CDKN2A
28886309	10.14715/cmb/2017.63.8.4	2018	The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.	CDKN2A
28905228	10.1007/s12032-017-1038-7	2018	Genetic susceptibility in childhood acute lymphoblastic leukemia.	CDKN2A
28947432	10.1158/1940-6207.CAPR-17-0121	2018	<i>IKZF1</i> Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities.	CDKN2A
28949402	10.1002/mc.22737	2018	Gain of function in the mouse model of a recurrent mutation p53<sup>N236S</sup> promotes the formation of double minute chromosomes and the oncogenic potential of p19<sup>ARF</sup>.	CDKN2A
29028122	10.1111/cup.13057	2018	Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature.	CDKN2A
29198127	10.4149/BLL_2017_116	2018	Immunohistochemical investigation of P16, P53 and Ki-67's prognostic values in diffuse large B-Cell lymphomas.	CDKN2A
29335448	10.1038/s41598-017-19127-7	2018	Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese.	CDKN2A
29575541	10.1111/ijlh.12805	2018	Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.	CDKN2A
29661169	10.1186/s12885-018-4304-y	2018	RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas.	CDKN2A
29726059	10.1002/gcc.6	2018	Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.	CDKN2A
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	CDKN2A
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	CDKN2A
30020823	10.1080/08880018.2018.1467986	2018	Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas.	CDKN2A
30203896	10.1002/gcc.22664	2018	Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases.	CDKN2A
26500062	10.1038/onc.2015.405	2017	Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.	CDKN2A
26724941	10.1007/s12026-015-8777-3	2017	hIgD promotes human Burkitt lymphoma Daudi cell proliferation by accelerated G1/S transition via IgD receptor activity.	CDKN2A
26773040	10.1182/blood-2015-09-672352	2017	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	CDKN2A
26872600	10.1016/j.jid.2016.01.028	2017	Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.	CDKN2A
26892479	10.3109/10428194.2016.1144881	2017	Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.	CDKN2A
26941364	10.1158/1055-9965.EPI-15-0528	2017	Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics.	CDKN2A
26957068	10.3760/cma.j.issn.0578-1310.2016.03.011	2017	[Copy number variations in pediatric ETV6/RUNX1 positive acute lymphoblastic leukemia].	CDKN2A
27059373	10.1093/jnci/djw036	2017	The Conundrum of Genetic Drivers in Benign Conditions.	CDKN2A
27070758	10.1016/j.leukres.2016.03.002	2017	Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.	CDKN2A
27125204	10.1038/leu.2016.70	2017	CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.	CDKN2A
27151989	10.3324/haematol.2016.143875	2017	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.	CDKN2A
27166996	10.18632/oncotarget.9197	2017	MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect.	CDKN2A
27184773	10.3109/08880018.2016.1161685	2017	Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.	CDKN2A
27229929	10.1186/s12885-016-2374-2	2017	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	CDKN2A
27351634	10.1080/17474086.2016.1199948	2017	Richter transformation of CLL.	CDKN2A
27473081	10.1007/s13277-016-5259-8	2017	Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.	CDKN2A
27622827	10.1016/j.clml.2016.08.016	2017	Aberrant p15, p16, p53, and DAPK Gene Methylation in Myelomagenesis: Clinical and Prognostic Implications.	CDKN2A
27694927	10.1038/leu.2016.271	2017	A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.	CDKN2A
27742070	10.1016/j.beha.2016.08.006	2017	Richter's syndrome: Novel and promising therapeutic alternatives.	CDKN2A
27750045	10.1016/j.ajpath.2016.07.027	2017	B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.	CDKN2A
27759694	10.1097/DAD.0000000000000738	2017	An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature.	CDKN2A
27759908	10.1002/pbc.26266	2017	Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis.	CDKN2A
27775850	10.1111/his.13106	2017	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).	CDKN2A
27957801	10.1002/pbc.26363	2017	Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues.	CDKN2A
27967319	10.2217/pgs-2016-0075	2017	Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemia.	CDKN2A
27979924	10.3324/haematol.2016.153023	2017	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.	CDKN2A
28003275	10.1101/cshperspect.a026286	2017	<i>TP53</i> Mutations in Hypodiploid Acute Lymphoblastic Leukemia.	CDKN2A
28115373	10.1182/blood-2016-10-706465	2017	The genetics and molecular biology of T-ALL.	CDKN2A
28126143	10.1016/j.medcli.2016.07.035	2017	[Copy number alterations in adult patients with mature B acute lymphoblastic leukemia treated with specific immunochemotherapy].	CDKN2A
28193567	10.1016/j.leukres.2017.01.034	2017	Genomic analysis of adult B-ALL identifies potential markers of shorter survival.	CDKN2A
28202519	10.1158/0008-5472.CAN-16-2571	2017	Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia.	CDKN2A
28210822	10.1007/s10147-017-1100-7	2017	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma.	CDKN2A
28219927	10.15252/embj.201695495	2017	Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.	CDKN2A
28359267	10.1186/s12885-017-3233-5	2017	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	CDKN2A
28425985	10.1038/cddis.2017.164	2017	The cellular senescence of leukemia-initiating cells from acute lymphoblastic leukemia is postponed by β-Arrestin1 binding with P300-Sp1 to regulate hTERT transcription.	CDKN2A
28439887	10.1111/bjh.14721	2017	Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.	CDKN2A
28476198	10.1016/j.arcmed.2016.12.002	2017	Copy Number Alterations Associated with Acute Lymphoblastic Leukemia in Mexican Children. A report from The Mexican Inter-Institutional Group for the identification of the causes of childhood leukemia.	CDKN2A
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	CDKN2A
28481918	10.1371/journal.pone.0177421	2017	Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population.	CDKN2A
28680000	10.11406/rinketsu.58.669	2017	Genetic heterogeneity of DLBCL, not otherwise specified.	CDKN2A
28819011	10.1182/blood-2017-04-779736	2017	<i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.	CDKN2A
25553294	10.3343/alm.2015.35.1.132	2016	Clinical relevance of high-resolution single nucleotide polymorphism array in patients with relapsed acute lymphoblastic leukemia with normal karyotype: a report of three cases.	CDKN2A
25573202	10.3109/10428194.2014.1003559	2016	Point mutations in TP53 but not in p15(Ink4b) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma.	CDKN2A
25784651	10.18632/oncotarget.2969	2016	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.	CDKN2A
25787150	10.1007/s00204-015-1500-2	2016	Long-term arsenite exposure induces premature senescence in B cell lymphoma A20 cells.	CDKN2A
25823025	10.1038/onc.2015.39	2016	Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.	CDKN2A
25903014	10.1186/s13045-015-0138-0	2016	Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A.	CDKN2A
25951811	10.1002/gcc.22251	2016	Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).	CDKN2A
25991819	10.1158/1078-0432.CCR-14-2116	2016	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	CDKN2A
26104880	10.1038/ncomms8553	2016	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.	CDKN2A
26106001	10.3960/jslrt.55.13	2016	Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.	CDKN2A
26194343	10.1002/cncr.29579	2016	Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.	CDKN2A
26199387	10.1158/1078-0432.CCR-15-0508	2016	Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome.	CDKN2A
26205622	10.1111/bjh.13613	2016	Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.	CDKN2A
26206799	10.3324/haematol.2015.130179	2016	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.	CDKN2A
26277549	10.1016/j.cancergen.2015.06.003	2016	Frequency of copy number abnormalities in common genes associated with B-cell precursor acute lymphoblastic leukemia cytogenetic subtypes in Brazilian children.	CDKN2A
26297264	10.1016/j.clml.2015.02.035	2016	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	CDKN2A
26350502	10.1007/s13402-015-0242-8	2016	DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas.	CDKN2A
26362858	10.1007/s12185-015-1858-1	2016	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	CDKN2A
26403224	10.1111/bjh.13763	2016	HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.	CDKN2A
26458445	10.11406/rinketsu.56.2056	2016	[Recent advancements in molecular cytogenetics for hematological malignancies: identification of novel PVT1 fusion genes].	CDKN2A
26463672	10.1038/srep15065	2016	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.	CDKN2A
26498513	10.3892/or.2015.4347	2016	Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.	CDKN2A
26527286	10.1158/0008-5472.CAN-15-1105	2016	A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution.	CDKN2A
26551670	10.1038/ng.3444	2016	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	CDKN2A
26575185	10.1371/journal.pone.0143343	2016	Somatic Mutation Allelic Ratio Test Using ddPCR (SMART-ddPCR): An Accurate Method for Assessment of Preferential Allelic Imbalance in Tumor DNA.	CDKN2A
26599546	10.1371/journal.pone.0139663	2016	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	CDKN2A
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	CDKN2A
26637365	10.1158/1535-7163.MCT-14-1065	2016	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.	CDKN2A
26642065	10.1097/GCO.0000000000000243	2016	Cyclin-dependent kinase pathways as targets for women's cancer treatment.	CDKN2A
26702065	10.1182/blood-2015-10-673236	2016	Targetable genetic features of primary testicular and primary central nervous system lymphomas.	CDKN2A
26773847	10.1002/gcc.22349	2016	Patterns and frequencies of acquired and constitutional uniparental isodisomies in pediatric and adult B-cell precursor acute lymphoblastic leukemia.	CDKN2A
26780579	10.1111/ajt.13558	2016	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features.	CDKN2A
26781410		2016	[Detection of copy number variations in pediatric ETV6/RUNX1-positive acute lymphoblastic leukemia with multiplex ligation-dependent probe amplification].	CDKN2A
26806743		2016	[Tal1 promotes proliferation of acute lymphoblastic leukemia Jurkat cells in vitro].	CDKN2A
26868379	10.1038/ncomms10635	2016	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology.	CDKN2A
26887776	10.1111/bjh.13925	2016	Genetic differences between paediatric and adult Burkitt lymphomas.	CDKN2A
27013922	10.2174/1389202916666151014221954	2016	Genetics of Bladder Malignant Tumors in Childhood.	CDKN2A
27040710	10.1053/j.seminoncol.2016.02.012	2016	Richter syndrome: pathogenesis and management.	CDKN2A
27090891	10.1186/s13045-016-0270-5	2016	Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	CDKN2A
27478369	10.4137/BBI.S30523	2016	Cluster Analysis of Tumor Suppressor Genes in Canine Leukocytes Identifies Activation State.	CDKN2A
24164743	10.1179/1607845413Y.0000000137	2015	CpG island methylator phenotype and its relationship with prognosis in adult acute leukemia patients.	CDKN2A
24365070	10.1016/j.tvjl.2013.11.004	2015	Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma.	CDKN2A
24633422	10.1007/s00268-014-2485-3	2015	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.	CDKN2A
24815345	10.1016/j.rvsc.2014.04.008	2015	Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells.	CDKN2A
24815848	10.1111/cts.12162	2015	Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.	CDKN2A
24832791	10.1002/gcc.22184	2015	Amplification of 2p as a genomic marker for transformation in lymphoma.	CDKN2A
24957142	10.1182/blood-2014-03-562918	2015	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	CDKN2A
24983247	10.1371/journal.pone.0101283	2015	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.	CDKN2A
25044358	10.1002/gcc.22201	2015	Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.	CDKN2A
25145835	10.1111/bjh.13079	2015	The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.	CDKN2A
25155625	10.1111/bjh.13089	2015	Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.	CDKN2A
25218362	10.1007/s11899-014-0223-4	2015	Risk factors for Richter syndrome in chronic lymphocytic leukemia.	CDKN2A
25261097	10.3324/haematol.2014.112912	2015	Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.	CDKN2A
25308604	10.1111/bjd.13476	2015	Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease.	CDKN2A
25320005	10.1158/0008-5472.CAN-14-0643	2015	Molecular characterization of chronic-type adult T-cell leukemia/lymphoma.	CDKN2A
25485910	10.1038/nm.3751	2015	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.	CDKN2A
25511139	10.1309/AJCPATRQWANW2O3N	2015	Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities.	CDKN2A
25542698	10.1016/j.leukres.2014.11.023	2015	Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.	CDKN2A
25572145	10.1042/BSR20140160	2015	Re-expression of HPV16 E2 in SiHa (human cervical cancer) cells potentiates NF-κB activation induced by TNF-α concurrently increasing senescence and survival.	CDKN2A
25587943	10.1080/15592294.2014.1003746	2015	Epigenetic regulation in human melanoma: past and future.	CDKN2A
25675863	10.1016/j.leukres.2015.01.008	2015	The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.	CDKN2A
25676421	10.1038/leu.2015.41	2015	Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice.	CDKN2A
25691468	10.1101/gad.255331.114	2015	The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis.	CDKN2A
25706938	10.1002/gcc.22246	2015	A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients.	CDKN2A
25746661	10.1016/j.yexmp.2015.03.006	2015	Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.	CDKN2A
25833113	10.1002/pbc.25523	2015	Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia.	CDKN2A
25860944	10.3390/ijms16047861	2015	Antiproliferative, antibacterial and antifungal activity of the lichen Xanthoria parietina and its secondary metabolite parietin.	CDKN2A
26022239	10.1182/blood-2015-02-628792	2015	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.	CDKN2A
26141385	10.1016/j.mrfmmm.2015.06.004	2015	The effect of age at exposure on the inactivating mechanisms and relative contributions of key tumor suppressor genes in radiation-induced mouse T-cell lymphomas.	CDKN2A
26500029	10.1016/j.tranon.2015.08.002	2015	Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms.	CDKN2A
23292502	10.3892/ijo.2012.1752	2014	Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts.	CDKN2A
23311322	10.3109/10428194.2013.764422	2014	Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis.	CDKN2A
23320886	10.3109/10428194.2013.765563	2014	Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a gene methylation study.	CDKN2A
23333812	10.1016/j.ygeno.2013.01.001	2014	Targeted resequencing of 9p in acute lymphoblastic leukemia yields concordant results with array CGH and reveals novel genomic alterations.	CDKN2A
23343657	10.1292/jvms.12-0351	2014	Simultaneous inactivation of the p16, p15 and p14 genes encoding cyclin-dependent kinase inhibitors in canine T-lymphoid tumor cells.	CDKN2A
23508010	10.3324/haematol.2013.085175	2014	Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.	CDKN2A
23547836	10.3109/10428194.2013.790543	2014	Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality.	CDKN2A
23688747	10.3760/cma.j.issn.0253-2727.2013.05.003	2014	[Comparison of clinical implications of p16 deletion in childhood and adult B-lineage acute lymphoblastic leukemia].	CDKN2A
23770345	10.1016/j.fct.2013.05.045	2014	Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells.	CDKN2A
23825691	10.1371/journal.pone.0067941	2014	Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf.	CDKN2A
23836053	10.1007/s10552-013-0256-3	2014	Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics.	CDKN2A
23873701	10.1002/gcc.22088	2014	BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma.	CDKN2A
23890198	10.1111/gtc.12079	2014	Inorganic arsenic exposure induces E2F-dependent G0/G1 arrest via an increase in retinoblastoma family protein p130 in B-cell lymphoma A20 cells.	CDKN2A
23989669	10.1007/s00277-013-1889-8	2014	Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion.	CDKN2A
23996088	10.1182/blood-2013-03-491316	2014	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.	CDKN2A
24030746	10.1038/modpathol.2013.156	2014	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.	CDKN2A
24064951	10.3892/or.2013.2734	2014	Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.	CDKN2A
24114011	10.1007/s13277-013-1195-z	2014	BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.	CDKN2A
24161991	10.18632/oncotarget.1541	2014	CDK6 and p16INK4A in lymphoid malignancies.	CDKN2A
24294363		2014	Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.	CDKN2A
24344258	10.1073/pnas.1321704111	2014	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	CDKN2A
24388756	10.1016/j.celrep.2013.12.027	2014	Genetics of follicular lymphoma transformation.	CDKN2A
24421328	10.1182/blood-2013-11-516229	2014	How we treat Richter syndrome.	CDKN2A
24429254	10.1016/j.molonc.2013.11.007	2014	TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.	CDKN2A
24449825	10.1158/1078-0432.CCR-13-2175	2014	Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.	CDKN2A
24528084	10.7314/apjcp.2014.15.1.75	2014	DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients.	CDKN2A
24612100	10.1111/cas.12388	2014	High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays.	CDKN2A
24619868	10.1002/gcc.22163	2014	Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.	CDKN2A
24678689	10.5858/arpa.2013-0101-RS	2014	Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review.	CDKN2A
24690081	10.1111/bjh.12851	2014	Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish.	CDKN2A
24753091	10.1002/ajh.23727	2014	Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia.	CDKN2A
24815991	10.1111/cas.12442	2014	Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis.	CDKN2A
24834146	10.3402/jev.v3.23034	2014	Anti-proliferative and anti-tumour effects of lymphocyte-derived microparticles are neither species- nor tumour-type specific.	CDKN2A
24913233	10.1084/jem.20132120	2014	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.	CDKN2A
24928937	10.1530/JOE-14-0159	2014	Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis.	CDKN2A
22588930		2013	[Cytogenetic differences between adults and children with acute lymphoblastic leukemia: eight-probe fluorescence in situ hybridization and karyotype analyses].	CDKN2A
22687603	10.1016/j.biochi.2012.05.029	2013	Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.	CDKN2A
22699455	10.1038/leu.2012.155	2013	Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.	CDKN2A
22726540	10.1186/1758-3284-4-38	2013	p16 overexpression in malignant and premalignant lesions of the oral and esophageal mucosa following allogeneic hematopoietic stem cell transplantation.	CDKN2A
22812491	10.3109/10428194.2012.713481	2013	Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.	CDKN2A
22837180	10.1158/1078-0432.CCR-12-0845	2013	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	CDKN2A
22889820	10.1038/leu.2012.227	2013	Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia.	CDKN2A
22994152	10.1111/bjh.12051	2013	Homozygous deletions of CDKN2A are present in all dic(9;20)(p13·2;q11·2)-positive B-cell precursor acute lymphoblastic leukaemias and may be important for leukaemic transformation.	CDKN2A
23016962	10.1111/bjh.12063	2013	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.	CDKN2A
23023710	10.1172/JCI61269	2013	The molecular basis of T cell acute lymphoblastic leukemia.	CDKN2A
23033441	10.1158/0008-5472.CAN-12-2579	2013	Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node.	CDKN2A
23044159	10.1016/j.bcmd.2012.09.005	2013	A case of childhood T cell acute lymphoblastic leukemia with a complex t(9;9) and homozygous deletion of CDKN2A gene associated with a Philadelphia-positive minor subclone.	CDKN2A
23060540		2013	Viral and molecular aspects of oral cancer.	CDKN2A
23178376	10.1016/j.exphem.2012.11.006	2013	Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.	CDKN2A
23225516	10.1002/gcc.22034	2013	Submicroscopic genomic imbalances in Burkitt lymphomas/leukemias: association with age and further evidence that 8q24/MYC translocations are not sufficient for leukemogenesis.	CDKN2A
23236167	10.1073/pnas.1210371110	2013	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.	CDKN2A
23275143	10.1007/s12032-012-0441-3	2013	Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.	CDKN2A
23341344	10.1002/gcc.22039	2013	The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.	CDKN2A
23354995	10.1007/s00277-012-1664-2	2013	Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia.	CDKN2A
23368921	10.1080/01635581.2013.741759	2013	Black raspberry-derived anthocyanins demethylate tumor suppressor genes through the inhibition of DNMT1 and DNMT3B in colon cancer cells.	CDKN2A
23373539	10.1111/bjh.12231	2013	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.	CDKN2A
23412789	10.1007/978-1-62703-281-0_10	2013	Copy number analysis in EBV-positive nodal peripheral T cell lymphoma, unspecified.	CDKN2A
23412790	10.1007/978-1-62703-281-0_11	2013	Mycosis fungoides and Sézary syndrome.	CDKN2A
23423784	10.1007/s12032-013-0489-8	2013	8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.	CDKN2A
23427295	10.1158/1535-7163.MCT-12-0903	2013	Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.	CDKN2A
23440244	10.1182/blood-2012-06-434365	2013	RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.	CDKN2A
23508829	10.1002/gcc.22054	2013	Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia.	CDKN2A
23512250	10.1093/jnci/djt042	2013	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.	CDKN2A
23687089	10.1182/blood-2013-03-491092	2013	Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.	CDKN2A
23695450	10.1097/MOH.0b013e3283623c61	2013	Early T-cell precursor acute lymphoblastic leukaemia.	CDKN2A
23900870	10.5114/pjp.2013.36199	2013	Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children.	CDKN2A
23961875	10.1111/bjh.12515	2013	Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.	CDKN2A
24004666	10.1182/blood-2013-03-489518	2013	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.	CDKN2A
24127483	10.1084/jem.20131448	2013	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	CDKN2A
20435627	10.3324/haematol.2009.011114	2012	Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.	CDKN2A
21785817	10.3892/ijmm.2011.756	2012	Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma.	CDKN2A
21796618	10.1002/ijc.26299	2012	Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.	CDKN2A
21796768	10.1002/pbc.23285	2012	Using MS-MLPA as an efficient screening tool for detecting 9p21 abnormalities in pediatric acute lymphoblastic leukemia.	CDKN2A
21882283	10.1002/gcc.20919	2012	Microarray-based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia.	CDKN2A
21900200	10.1182/blood-2011-03-337501	2012	Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion.	CDKN2A
21921043	10.1182/blood-2011-04-345595	2012	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.	CDKN2A
21986948	10.1038/onc.2011.462	2012	Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.	CDKN2A
21987080	10.1007/s10552-011-9848-y	2012	Haplotypes of DNA repair and cell cycle control genes, X-ray exposure, and risk of childhood acute lymphoblastic leukemia.	CDKN2A
22047081	10.1089/dna.2011.1314	2012	Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.	CDKN2A
22072402	10.1002/gcc.20944	2012	High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.	CDKN2A
22134481	10.1158/1078-0432.CCR-11-1227	2012	CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.	CDKN2A
22326754	10.1016/j.ajpath.2012.01.004	2012	A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.	CDKN2A
22410569	10.1167/iovs.11-7668	2012	Multigene methylation analysis of ocular adnexal MALT lymphoma and their relationship to Chlamydophila psittaci infection and clinical characteristics in South Korea.	CDKN2A
22490415		2012	Integrase interactor 1 regulates proliferation, apoptosis and invasion in gastric cancer cells.	CDKN2A
22564515	10.1503/cjs.002310	2012	Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?	CDKN2A
22591685	10.1016/j.leukres.2012.04.018	2012	Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.	CDKN2A
22619049	10.1002/gcc.21970	2012	Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.	CDKN2A
22851563	10.1200/JCO.2011.40.3907	2012	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.	CDKN2A
22855598	10.1182/blood-2012-03-419937	2012	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.	CDKN2A
22975378	10.1016/j.ccr.2012.07.014	2012	Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.	CDKN2A
18928598		2011	[Demethylation and transcription of p16 gene in malignant lymphoma cell line CA46 induced by EGCG].	CDKN2A
19586936	10.3324/haematol.2009.007526	2011	Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.	CDKN2A
19626541	10.1080/10428190903111914	2011	Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival.	CDKN2A
20065082	10.3324/haematol.2009.010413	2011	Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults.	CDKN2A
20416177		2011	[Arsenic trioxide reverses hypermethylation of p16 and activates its transcription in malignant lymphoma cell line CA46].	CDKN2A
20658957	10.3109/10428194.2010.505820	2011	Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome.	CDKN2A
20815030	10.1002/gcc.20818	2011	Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia.	CDKN2A
20846793	10.1016/j.prp.2010.07.007	2011	Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis.	CDKN2A
20960563	10.1002/gcc.20831	2011	Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.	CDKN2A
20973102	10.1002/pbc.22810	2011	Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A.	CDKN2A
21035853	10.1016/j.leukres.2010.10.001	2011	Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma.	CDKN2A
21067440	10.3109/10428194.2010.528095	2011	Study of specific genetic and epigenetic variables in multiple myeloma.	CDKN2A
21082971	10.1586/ehm.09.16	2011	New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.	CDKN2A
21088137	10.1182/blood-2010-07-297861	2011	Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.	CDKN2A
21098271	10.1073/pnas.1006981107	2011	Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.	CDKN2A
21127431	10.1097/MPH.0b013e3181edf543	2011	The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.	CDKN2A
21174181	10.1007/s12253-010-9335-x	2011	Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China.	CDKN2A
21200153	10.4161/cc.10.1.14446	2011	Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines.	CDKN2A
21242996	10.1038/leu.2010.318	2011	The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial.	CDKN2A
21248843	10.1038/nature09733	2011	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	CDKN2A
21263154	10.1182/blood-2010-08-301267	2011	Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.	CDKN2A
21325069	10.1158/1078-0432.CCR-10-2945	2011	Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus.	CDKN2A
21356189	10.1016/j.cancergencyto.2010.10.007	2011	Implementation of high resolution single nucleotide polymorphism array analysis as a clinical test for patients with hematologic malignancies.	CDKN2A
21375435	10.3109/10428194.2011.559802	2011	Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas.	CDKN2A
21410763	10.1111/j.1600-0625.2010.01226.x	2011	Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.	CDKN2A
21414664	10.1016/j.leukres.2011.02.020	2011	A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.	CDKN2A
21427293	10.1182/blood-2010-09-309831	2011	Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.	CDKN2A
21482711	10.1182/blood-2010-10-314674	2011	Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia.	CDKN2A
21504712	10.1016/j.cancergen.2010.12.010	2011	High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.	CDKN2A
21518927	10.1182/blood-2010-08-301135	2011	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.	CDKN2A
21527530	10.1182/blood-2011-01-329961	2011	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.	CDKN2A
21549623	10.1016/j.bcmd.2011.04.003	2011	PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia.	CDKN2A
21592569	10.1016/j.leukres.2011.04.015	2011	Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia.	CDKN2A
21622646	10.1182/blood-2010-09-305383	2011	Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia.	CDKN2A
21638516	10.1002/gcc.20893	2011	Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.	CDKN2A
21646720	10.1172/JCI45682	2011	The LRF transcription factor regulates mature B cell development and the germinal center response in mice.	CDKN2A
21670474	10.1182/blood-2010-11-320309	2011	Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment.	CDKN2A
21747916	10.1371/journal.pone.0021625	2011	The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression.	CDKN2A
21889209	10.1016/j.leukres.2011.07.034	2011	Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.	CDKN2A
19594747	10.1111/j.1365-2141.2009.07791.x	2010	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	CDKN2A
19728399	10.1002/hon.921	2010	Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samples.	CDKN2A
19759554	10.1038/jid.2009.306	2010	Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides.	CDKN2A
19828704	10.1182/blood-2009-08-231217	2010	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).	CDKN2A
19893343	10.3343/kjlm.2009.29.5.371	2010	[Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia].	CDKN2A
19935700	10.1038/onc.2009.423	2010	p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis.	CDKN2A
19942610	10.1093/carcin/bgp296	2010	Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E.	CDKN2A
20008304	10.1182/blood-2009-04-214718	2010	Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.	CDKN2A
20008789	10.1182/blood-2009-05-222166	2010	Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.	CDKN2A
20019193	10.2353/ajpath.2010.090236	2010	Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma.	CDKN2A
20068150	10.1158/0008-5472.CAN-09-2736	2010	Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.	CDKN2A
20073070	10.1002/gcc.20743	2010	ABL1 rearrangements in T-cell acute lymphoblastic leukemia.	CDKN2A
20095847	10.1667/RR1855.1	2010	Two loci controlling susceptibility to radiation-induced lymphomagenesis on mouse chromosome 4: cdkn2a, a candidate for one locus, and a novel locus distinct from cdkn2a.	CDKN2A
20118908	10.1038/modpathol.2009.196	2010	CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.	CDKN2A
20143914	10.1089/gtmb.2009.0145	2010	Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia.	CDKN2A
20237506	10.1038/leu.2010.39	2010	Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.	CDKN2A
20331971	10.1016/j.bbrc.2010.03.110	2010	Functional availability of gamma-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a.	CDKN2A
20332669	10.1159/000278291	2010	Expression and alteration of p16 in diffuse large B cell lymphoma.	CDKN2A
20417863	10.1016/j.cancergencyto.2010.01.014	2010	Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.	CDKN2A
20421449	10.1182/blood-2010-01-263806	2010	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.	CDKN2A
20435884	10.1182/blood-2009-10-247122	2010	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.	CDKN2A
20445578	10.1038/leu.2010.87	2010	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	CDKN2A
20453839	10.1038/ng.585	2010	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.	CDKN2A
20513752	10.1093/hmg/ddq224	2010	The correlation pattern of acquired copy number changes in 164 ETV6/RUNX1-positive childhood acute lymphoblastic leukemias.	CDKN2A
20544841	10.1002/gcc.20780	2010	High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes.	CDKN2A
20562326	10.1182/blood-2010-01-264093	2010	Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia.	CDKN2A
20617153	10.1155/2010/369534	2010	Detection of fetomaternal genotype associations in early-onset disorders: evaluation of different methods and their application to childhood leukemia.	CDKN2A
20620602	10.1016/j.cancergencyto.2010.03.009	2010	Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.	CDKN2A
20648475	10.1002/hep.23793	2010	Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.	CDKN2A
20800819	10.1016/S1877-1173(10)92006-1	2010	Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia.	CDKN2A
18803328	10.1002/gcc.20616	2009	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks.	CDKN2A
18820662	10.1038/modpathol.2008.159	2009	Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States.	CDKN2A
18828156	10.1002/gcc.20617	2009	Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status.	CDKN2A
18838613	10.1182/blood-2008-07-166801	2009	A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.	CDKN2A
18927438	10.1182/blood-2008-08-170928	2009	Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.	CDKN2A
18984860	10.1182/blood-2008-07-170183	2009	Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.	CDKN2A
18989737	10.1007/s10038-008-0340-9	2009	Nonparametric estimation of LOH using Affymetrix SNP genotyping arrays for unpaired samples.	CDKN2A
18997617	10.1097/PAI.0b013e31818a9d90	2009	Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after Hodgkin lymphoma.	CDKN2A
19020554	10.1038/jid.2008.357	2009	Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type.	CDKN2A
19028987	10.1101/sqb.2008.73.039	2009	The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.	CDKN2A
19047137	10.1158/0008-5472.CAN-08-2263	2009	The ARF tumor suppressor can promote the progression of some tumors.	CDKN2A
19064397	10.3816/CLM.2008.n.048	2009	Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach.	CDKN2A
19099554	10.1186/1471-2407-8-379	2009	Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in classical Hodgkin lymphoma in China.	CDKN2A
19174606	10.1159/000195698	2009	Methylation of p16INK4A and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-zone B-cell lymphomas.	CDKN2A
19217041	10.1002/dc.21022	2009	Cytologic and immunocytochemical features of EBV negative primary effusion lymphoma: report on seven Japanese cases.	CDKN2A
19239430	10.1111/j.1600-0463.2008.00017.x	2009	Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.	CDKN2A
19347729	10.1080/10428190902756594	2009	CpG island methylation patterns in chronic lymphocytic leukemia.	CDKN2A
19369625	10.1309/AJCPXLY46UPFLISC	2009	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.	CDKN2A
19380031	10.1016/j.cancergencyto.2008.12.012	2009	Hyperdiploidy with trisomy 9 and deletion of the CDKN2A locus in T-cell acute lymphoblastic leukemia.	CDKN2A
19389505	10.1016/j.cancergencyto.2009.01.002	2009	High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage.	CDKN2A
19424578	10.3892/ijo_00000290	2009	Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.	CDKN2A
19470474	10.1073/pnas.0811761106	2009	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	CDKN2A
19470736	10.1158/1078-0432.CCR-08-2196	2009	Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.	CDKN2A
19484265	10.1007/s00439-009-0689-7	2009	Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.	CDKN2A
19494841	10.1038/leu.2009.120	2009	Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma.	CDKN2A
19567676	10.1158/0008-5472.CAN-09-0145	2009	Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.	CDKN2A
19602459	10.1016/j.cancergencyto.2009.03.005	2009	Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia.	CDKN2A
19608668	10.3324/haematol.2009.007260	2009	Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.	CDKN2A
19639175	10.3892/ijo_00000366	2009	Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma.	CDKN2A
19665068	10.1016/j.cancergencyto.2009.04.021	2009	ETV6-RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis.	CDKN2A
19676100	10.1002/mc.20568	2009	Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.	CDKN2A
19759355	10.1182/blood-2009-07-233346	2009	Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.	CDKN2A
19837270	10.1016/j.cancergencyto.2009.06.013	2009	Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.	CDKN2A
17475325	10.1016/j.leukres.2007.03.021	2008	Does p16ink4a expression increase with the number of cell doublings in normal and malignant lymphocytes?	CDKN2A
17900658	10.1016/j.humpath.2007.05.009	2008	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.	CDKN2A
18185524	10.1038/sj.leu.2405082	2008	Cooperative genetic defects in TLX3 rearranged pediatric T-ALL.	CDKN2A
18245527	10.1158/1078-0432.CCR-07-1246	2008	Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells.	CDKN2A
18246599	10.1016/j.leukres.2006.12.007	2008	Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma.	CDKN2A
18287131	10.3324/haematol.12251	2008	Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.	CDKN2A
18311490	10.1007/s00428-008-0593-x	2008	Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas.	CDKN2A
18328560	10.1016/j.leukres.2008.01.014	2008	CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.	CDKN2A
18363431	10.1667/RR1180.1	2008	Analysis of changes in DNA copy number in radiation-induced thymic lymphomas of susceptible C57BL/6, resistant C3H and hybrid F1 Mice.	CDKN2A
18421954		2008	[Prognosis and molecular pathogenesis of adult T-cell leukemia/lymphoma].	CDKN2A
18458336	10.1073/pnas.0800408105	2008	Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.	CDKN2A
18467333	10.1074/jbc.M709695200	2008	Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.	CDKN2A
18489987	10.1016/j.bbmt.2008.02.015	2008	High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.	CDKN2A
18519632	10.1101/gad.1673908	2008	Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.	CDKN2A
18539616	10.1093/annonc/mdn374	2008	Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.	CDKN2A
18596985	10.1371/journal.pone.0002542	2008	The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence.	CDKN2A
18617057	10.1016/j.cancergencyto.2008.04.003	2008	Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution.	CDKN2A
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	CDKN2A
18648000	10.1093/jncimonographs/lgn015	2008	Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice.	CDKN2A
18656692	10.1016/j.cancergencyto.2008.05.001	2008	Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.	CDKN2A
18688286	10.1172/JCI35798	2008	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	CDKN2A
18755985	10.1182/blood-2008-02-142190	2008	The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.	CDKN2A
18784434	10.1159/000155144	2008	Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma.	CDKN2A
18784766		2008	The toxicology and carcinogenesis study of phenolphthalein (CAS No. 77-09-8) in genetically modified haploinsufficient p16(Ink4a)/p19(Arf) mice (feed study).	CDKN2A
18784769		2008	NTP report on the toxicology and carcinogenesis study of benzene (CAS No. 71-43-2) in genetically modified haploinsufficient p16 Ink4a/p19 Arf mice (gavage study).	CDKN2A
19039135	10.1126/science.1164266	2008	Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.	CDKN2A
17008550	10.1182/blood-2006-02-003236	2007	Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia.	CDKN2A
17428253	10.1111/j.1349-7006.2007.00482.x	2007	Telomere dysfunction and inactivation of the p16(INK4a)/Rb pathway in pyothorax-associated lymphoma.	CDKN2A
17486064	10.1038/sj.onc.1210507	2007	Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.	CDKN2A
16320052	10.1007/s00277-005-0041-9	2006	Methylation of the INK4A/ARF locus in blood mononuclear cells.	CDKN2A
16357845	10.1038/modpathol.3800505	2006	Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas.	CDKN2A
15370242	10.1080/10428190410001714025	2005	p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia.	CDKN2A
15649253	10.1111/j.1349-7006.2005.00003.x	2005	Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.	CDKN2A
15800668	10.1038/sj.leu.2403729	2005	G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.	CDKN2A
15813917	10.1111/j.1600-0609.2005.00417.x	2005	Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders.	CDKN2A
15878620	10.1016/j.leukres.2005.04.006	2005	Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.	CDKN2A
12459645	10.1097/00008390-200212000-00005	2003	The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers.	CDKN2A
11804283	10.1023/a:1012946812930	2002	Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type.	CDKN2A
11830494	10.1182/blood.v99.4.1411	2002	p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways.	CDKN2A
11839577	10.1016/S0002-9440(10)64876-6	2002	Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.	CDKN2A
11850526	10.1038/labinvest.3780405	2002	p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides.	CDKN2A
11874489	10.1046/j.0022-202x.2001.01682.x	2002	Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.	CDKN2A
11889694		2002	[Expression of the protein marker p16INK4a in the cervix uteri cancer].	CDKN2A
12036898	10.1182/blood.v99.12.4629	2002	Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia.	CDKN2A
12060387	10.1046/j.1523-1747.2002.01785.x	2002	Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma.	CDKN2A
12127556	10.1016/s0145-2126(02)00020-6	2002	Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.	CDKN2A
12149228	10.1182/blood-2002-02-0382	2002	ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.	CDKN2A
12357355	10.1038/sj.leu.2402697	2002	Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.	CDKN2A
7624129		1995	A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.	CDKN2A
